Cingulate Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 31.9K | $198.02K | 0.00% | New | 2026-03-31 |
| StateStreet | passive | 27.6K | $171.32K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -0.53 | -0.95 | -80.38% |
| 2026-03-18 | -1.55 | -0.84 | +45.81% |
| 2025-11-13 | -0.75 | -1.35 | -79.52% |
| 2025-08-19 | -0.82 | -1.09 | -32.52% |
| 2025-05-08 | -0.98 | -1.04 | -6.12% |
| 2025-03-27 | -1.53 | -2.30 | -50.65% |
| 2024-11-07 | -2.22 | -1.83 | +17.57% |
| 2024-08-13 | -4.92 | -5.47 | -11.18% |
| 2024-05-08 | -12.48 | -7.20 | +42.31% |
| 2024-04-01 | -52.72 | -19.20 | +63.58% |
| 2023-11-13 | -90.40 | -72.00 | +20.35% |
| 2023-08-14 | -81.60 | -136.80 | -67.65% |
| 2023-05-10 | -77.60 | -84.00 | -8.25% |
| 2023-03-10 | -84.80 | -96.00 | -13.21% |
| 2022-11-14 | -88.80 | -86.40 | +2.70% |
| 2022-08-11 | -139.20 | -86.40 | +37.93% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CING | -22.53% | -34.07% | -4.15% | +6.12% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -25.50% | -29.43% | -0.70% | -6.57% |